ad

3 Senior Living Homes Builder, Global IT Services Leader and Branded Medicines Company Stocks With a Strong Future Roadmap: Ashiana Housing, Tata Consultancy Services and Emcure Pharmaceuticals

Ashiana Housing, Tata Consultancy Services and Emcure Pharmaceuticals: ROE of 13.6% to 43.4% and FY22 to FY26 revenue CAGR of 8.5% to 50.2%. Prices as of 16 Nov 2026.


17 Nov 2026 • 2:52 pm

3 Senior Living Homes Builder, Global IT Services Leader and Branded Medicines Company Stocks With a Strong Future Roadmap: Ashiana Housing, Tata Consultancy Services and Emcure Pharmaceuticals

Quick Answer

The three senior housing, IT and medicine stocks to watch are Ashiana Housing, Tata Consultancy Services and Emcure Pharmaceuticals. Their return on equity ranges from 13.6% to 43.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 50.2%. Tata Consultancy Services has the highest return on equity at 43.4%, while Ashiana Housing has the fastest revenue growth at 50.2% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.

Senior housing, IT and medicine stocks bring together companies with a visible plan for the years ahead. Ashiana Housing, Tata Consultancy Services and Emcure Pharmaceuticals cover a residential developer, an IT services company and a pharmaceuticals company.

This list covers three senior housing, IT and medicine stocks with complete current figures: Ashiana Housing, Tata Consultancy Services and Emcure Pharmaceuticals. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Senior Housing, IT and Medicine Stocks?

Senior housing, IT and medicine stocks are listed companies that build and sell apartments and senior living homes, provide IT services and consulting to large global clients, and make and sell medicines in India and global markets. Their earnings depend on home sales, client technology programmes and medicine demand.

Senior Housing, IT and Medicine Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Ashiana Housing 352.45 3,586 30.3 30.7 13.6 0.35
Tata Consultancy Services 2,405 904,522 17.4 17.6 43.4 0.10
Emcure Pharmaceuticals 2,338.8 33,487 32.9 36.0 18.7 0.31

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing senior housing, IT and medicine stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Senior Housing, IT and Medicine Stocks Have a Strong Roadmap in India?

Senior housing, IT and medicine stocks have a strong roadmap in India because steady demand for new homes, large client technology programmes and wider access to medicines keep widening the market for these companies.

  • Residential projects. Families look for well planned homes.
  • IT services. Large clients run long digital programmes.
  • Medicines. Hospitals and patients need reliable supply.

Why Ashiana Housing Features Among These Senior Housing, IT and Medicine Stocks

Among the senior housing, IT and medicine stocks on this list, Ashiana Housing develops mid-income residential projects and senior living communities in cities such as the Delhi region, Jaipur and Chennai. It is known for its focus on construction quality and timely delivery.

The company has a return on equity of 13.6%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 3,586 crore. The stock trades at a P/E of 30.3, below the industry P/E of 30.7.

Revenue rose from Rs 234 crore in FY22 to Rs 1,187 crore in FY26, a compound annual growth rate of 50.2%. Net profit grew from Rs 27.9 crore in FY23 to Rs 118 crore in FY26, which works out to a compound annual growth rate of 61.7%.

Roadmap: The company is launching new phases in established markets and growing its senior living portfolio. A reputation for delivery supports sales in its projects.

What to watch: Track sales bookings, project launches and deliveries.

Why Tata Consultancy Services Features Among These Senior Housing, IT and Medicine Stocks

Among the home builder, software giant and drug maker shares on this list, Tata Consultancy Services is India's largest information technology services company, offering consulting, application development, cloud, data and business process services to global clients from the Tata group.

Revenue rose from Rs 195,772 crore in FY22 to Rs 271,423 crore in FY26, a compound annual growth rate of 8.5%. Net profit grew from Rs 38,449 crore in FY22 to Rs 49,454 crore in FY26, which works out to a compound annual growth rate of 6.5%.

The company has a return on equity of 43.4%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 904,522 crore. The stock trades at a P/E of 17.4, below the industry P/E of 17.6.

Roadmap: The company is investing in artificial intelligence, cloud and data capabilities and in large multi-year transformation programmes with global clients. A broad client base across industries gives its revenue stability.

What to watch: Track order book trends, demand for artificial intelligence services and currency movements.

Why Emcure Pharmaceuticals Features Among These Senior Housing, IT and Medicine Stocks

Among the three companies on this list, Emcure Pharmaceuticals, based in Pune, sells branded generics in India through marketing arms such as Zuventus and Avet, and also serves Europe, Canada and other markets.

In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%.

Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0.

Roadmap: It is strengthening its domestic branded portfolio in women's health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.

What to watch: Look at the growth of the India branded business and the pace of new launches abroad.

Ashiana Housing vs Tata Consultancy Services vs Emcure Pharmaceuticals on Key Financials

The table below sets the three senior housing, IT and medicine stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Ashiana Housing 234 1,187 50.2% 118 9.9%
Tata Consultancy Services 195,772 271,423 8.5% 49,454 18.2%
Emcure Pharmaceuticals 5,919 9,335 12.1% 941 10.1%

Tata Consultancy Services posts the highest return on equity in this group at 43.4%. Tata Consultancy Services has the largest FY26 revenue at Rs 271,423 crore, and Ashiana Housing shows the fastest revenue growth with a 50.2% compound annual rate. A useful habit with senior housing, IT and medicine stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Senior Housing, IT and Medicine Stocks

Every theme carries risks that deserve a check before any decision. For these senior housing, IT and medicine stocks, the main points are:

  • Housing cycles. Real estate and building demand can vary with rates and sentiment.
  • Client spending. Technology budgets can vary with global conditions.
  • Regulatory approvals. Plant inspections and approvals can affect supplies.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter senior housing, IT and medicine stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Senior Housing, IT and Medicine Stocks

Senior housing, IT and medicine stocks suit investors who prefer to study business strength before price moves. Ashiana Housing, Tata Consultancy Services and Emcure Pharmaceuticals each have a clear plan to grow. Based on the 16 November 2026 close, Ashiana Housing trades at Rs 352.45, Tata Consultancy Services at Rs 2,405 and Emcure Pharmaceuticals at Rs 2,338.8.

Download the Univest iOS App or Univest Android App to track senior housing, IT and medicine stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are senior housing, IT and medicine stocks?

Ans. Senior housing, IT and medicine stocks are listed companies that build and sell apartments and senior living homes, provide IT services and consulting to large global clients, and make and sell medicines in India and global markets. Their earnings depend on home sales, client technology programmes and medicine demand. This list looks at three of them, Ashiana Housing, Tata Consultancy Services and Emcure Pharmaceuticals, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.

Which senior housing, IT and medicine stocks are covered in this list?

Ans. This list covers Ashiana Housing, Tata Consultancy Services and Emcure Pharmaceuticals. Based on the 16 November 2026 close, Ashiana Housing traded at Rs 352.45, Tata Consultancy Services at Rs 2,405 and Emcure Pharmaceuticals at Rs 2,338.8. Their return on equity ranges from 13.6% to 43.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 50.2%.

Why do senior housing, IT and medicine stocks have a strong future roadmap in India?

Ans. Senior housing, IT and medicine stocks have a strong roadmap in India because steady demand for new homes, large client technology programmes and wider access to medicines keep widening the market for these companies. The main drivers are as follows. Residential projects. Families look for well planned homes. IT services. Large clients run long digital programmes. Medicines. Hospitals and patients need reliable supply. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Ashiana Housing performed financially?

Ans. Revenue rose from Rs 234 crore in FY22 to Rs 1,187 crore in FY26, a compound annual growth rate of 50.2%. Net profit grew from Rs 27.9 crore in FY23 to Rs 118 crore in FY26, which works out to a compound annual growth rate of 61.7%. The company has a return on equity of 13.6%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 3,586 crore. The stock trades at a P/E of 30.3, below the industry P/E of 30.7. Looking ahead, the company is launching new phases in established markets and growing its senior living portfolio. A reputation for delivery supports sales in its projects.

How has Tata Consultancy Services performed financially?

Ans. Revenue rose from Rs 195,772 crore in FY22 to Rs 271,423 crore in FY26, a compound annual growth rate of 8.5%. Net profit grew from Rs 38,449 crore in FY22 to Rs 49,454 crore in FY26, which works out to a compound annual growth rate of 6.5%. The company has a return on equity of 43.4%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 904,522 crore. The stock trades at a P/E of 17.4, below the industry P/E of 17.6. Looking ahead, the company is investing in artificial intelligence, cloud and data capabilities and in large multi-year transformation programmes with global clients. A broad client base across industries gives its revenue stability.

How has Emcure Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women's health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.

What risks should investors check before buying senior housing, IT and medicine stocks?

Ans. Investors should check a few risks before buying senior housing, IT and medicine stocks. Housing cycles. Real estate and building demand can vary with rates and sentiment. Client spending. Technology budgets can vary with global conditions. Regulatory approvals. Plant inspections and approvals can affect supplies. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of senior housing, IT and medicine stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down